BioMarin Pharmaceuticals Inc

BMRNNASDAQ • USD
ThemeBiotech - Drug Development›Rare Disease Therapeutics
65.61 USD
↘ 0.51 (0.77%)AT CLOSE (11:59 AM EDT)
65.74
↗ 0.13 (0.19%)
POST MARKET (AS OF 07:58 PM EDT)
Post Market
AS OF 07:58 PM EDT
65.74
↗ 0.13 (0.19%)
🔴Market: CLOSED

BMRN is currently priced at $65.62. The stock presents a mixed profile: our models indicate a Buy for technical indicators, while underlying fundamentals flash a Sell. Key drivers include a bullish Golden Cross on the moving averages and bullish moving average alignment. BMRN is fairly valued relative to its sector peers based on current multiples.

Technical & fundamental data as of Aug 26, 2026.

Open?$65.62
High?$66.53
Low?$65.33
Prev. Close?$66.12
Volume?1.9M
Avg. Volume?2.1M
VWAP?$65.90
Rel. Volume?0.89x
Bid / Ask
Bid?$65.00 × 100
Ask?$67.00 × 1.7K
Spread?$2.00
Midpoint?$66.00
Valuation & Ratios
Market Cap?12.7B
Shares Out?193.6M
Float?192.0M
Float %?99.3%
P/E Ratio?174.04
P/B Ratio?2.01
EPS?$0.38
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
Themes
Biotech - Drug Development›Rare Disease TherapeuticsHealthcare - Genomics & Precision Medicine›Gene Therapy & Gene Editing
Employees
3.2K
Market Cap
12.8B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.biomarin.com
Listed
1999-07-23
Address
105 DIGITAL DRIVE
NOVATO, CA 94949
Phone: (415) 506-6700
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
23
Z-Score?
36
Momentum?
18
Short Sent.?
79
Piotroski F-Score?3/9Weak
Altman Z-Score?2.02Grey
Confidence?66%Moderate
Full Fundamental Analysis →
Short InterestElevated
Short % of Float?5.31%Elevated
Short Interest?10.2M
Days to Cover?3.7
Free Float192.0M
Avg Daily Volume2.8M
Settlement Date2026-08-14
Financial Health
Current Ratio?2.39Strong
Quick Ratio?1.32Adequate
Cash Ratio?0.53Adequate
Debt/Equity?0.66Moderate
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
Peers
100
S&P
3
174.0PRICEY▾
P/B?
Peers
100
S&P
74
2.01CHEAP▾
P/S?
Peers
100
S&P
41
3.73FAIR▾
P/FCF?
Peers
100
S&P
66
17.2CHEAP▾
EV/EBITDA?
Peers
100
S&P
3
52.4HIGH▾
EV/Sales?
Peers
100
S&P
38
4.70FAIR▾
Returns & Efficiency
ROE?
Peers
50
S&P
16
1.2%WEAK▾
ROA?
Peers
50
S&P
10
0.6%WEAK▾
Cash Flow & Enterprise
FCF?$738.2M
Enterprise Value?$16.0B
Fundamentals ratios updated end of day
MarketsMoversWatchlist